Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

Baron, Frédéric; Storb, R.

doi:10.1016/j.ymthe.2005.09.011

Letter to the editor (Scientific journals)

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

Baron, Frédéric; Storb, R.

2006 • In Molecular Therapy, 13 (1), p. 26-41

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/102045

DOI
10.1016/j.ymthe.2005.09.011

PubMed
16280257

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

BaronMolTher06.pdf

Publisher postprint (322.19 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

hematopoietic cell transplantation; nonmyeloablative conditioning; mixed chimerism; graft-versus-tumor effects; graft-versus-host disease

Abstract :

[en] Allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning regimens has been an effective treatment for many patients with hematologic malignancies or inherited blood disorders. Unfortunately, such regimens have been associated with significant toxicity, limiting their use to otherwise healthy, relatively young patients. In an attempt to extend treatment by allogeneic HCT to older patients and those with comorbid conditions, several groups of investigators have developed reduced-intensity or truly nonmyeloablative conditioning regimens, lacking such toxicity. Analogous to conventional regimens, reduced-intensity regimens both eliminated host-versus-graft (rejection) reactions and produced major anti-tumor effects. In contrast, nonmyeloablative regimens have relied on optimizing both pre-and posttransplant immunosuppression to overcome host-versus-g raft reactions, while anti-tumor responses have depended mainly on immune-mediated graft-versus-tumor effects. In this review, we define reduced-intensity and truly nonmyeloablative regimens, describe the preclinical development and clinical application of a very low intensity nonmyeloablative regimen, and review results with reduced-intensity regimens in patients with hematologic malignancies or inherited blood disorders.

Disciplines :

Biotechnology
Microbiology
Genetics & genetic processes

Author, co-author :

Baron, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie

Storb, R.

Language :

English

Title :

Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders

Publication date :

January 2006

Journal title :

Molecular Therapy

ISSN :

1525-0016

eISSN :

1525-0024

Publisher :

Academic Press Inc Elsevier Science, San Diego, United States - California

Volume :

Issue :

Pages :

26-41

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 09 November 2011

Statistics

Number of views

73 (1 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

F. Baron R. Storb Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: A review Semin. Immunopathol. 26 2004 71-94
P.L. Weiden et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N. Engl. J. Med. 300 1979 1068-1073
P.L. Weiden K.M. Sullivan N. Flournoy R. Storb E.D. Thomas The Seattle Marrow Transplant Team Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation N. Engl. J. Med. 304 1981 1529-1533
P.J. Martin et al. HLA-identical marrow transplantation during accelerated phase chronic myelogenous leukemia: Analysis of survival and remission duration Blood 72 1988 1978-1984
J.M. Goldman et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion Ann. Intern. Med. 108 1988 806-814
K.C. Hsu et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes Blood 105 2005 4878-4884
H.J. Kolb et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia Blood 86 1995 2041-2050
H.J. Kolb C. Schmidt A.J. Barrett D.J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood 103 2004 767-776
K.S. Peggs S. Mackinnon D.C. Linch The role of allogeneic transplantation in non-Hodgkin's lymphoma Br. J. Haematol. 128 2005 153-168
H.M. Lokhorst et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome J. Clin. Oncol. 18 2000 3031-3037
R. Or et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood 101 2003 441-445
S. Giralt et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
E. Morris et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma Blood 104 2004 3865-3871
C. Hallemeier et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants Biol. Blood Marrow Transplant 10 2004 310-319
I.F. Khouri Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality Blood 98 2001 3595-3599
P.A. McSweeney et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
R. Childs et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
L. Burroughs R. Storb Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: Separating graft-versus-leukemia effects from graft-versus-host disease Curr. Opin. Hematol. 12 2005 45-54
R.F. Storb R. Champlin S.R. Riddell M. Murata S. Bryant E.H. Warren Non-myeloablative transplants for malignant disease G.P. Schechter V.C. Broudy M.E. Williams Hematology 2001: American Society of Hematology Education Program Book 2001 Am. Soc. Hematol. Washington, DC 375-391
S. Giralt et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531-4536
N.T. Ueno Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood 102 2003 3829-3836
S. Slavin et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
P.D. Kottaridis et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
M. Girgis et al. Chimerism and clinical outcomes of 110 unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide Blood 105 2005 3035-3041
J. Schetelig et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group J. Clin. Oncol. 21 2003 2747-2753
P. Corradini et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells J. Clin. Oncol. 22 2004 2172-2176
R. Storb et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048-3054
R. Storb et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation Blood 94 1999 1131-1136
F. Baron et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J. Clin. Oncol. 23 2005 1993-2003
R. Storb et al. What radiation dose for DLA-identical canine marrow grafts? Blood 72 1988 1300-1304
C. Yu et al. DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment Blood 86 1995 4376-4381
W.J. Hogan et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates Biol. Blood Marrow Transplant 9 2003 489-495
R. Storb et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant Blood 94 1999 2523-2529
W.A. Bethge et al. Selective T-cell ablation with bismuth-213-labeled anti-TCR αβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation Blood 101 2003 5068-5075
B.J. Hartnett et al. Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cells Biol. Blood Marrow Transplant 8 2002 188-197
R. Diaconescu et al. What role for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation? Biol. Blood Marrow Transplant 11 2005 335-344
C.-Q. Xun et al. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation 73 2002 310-313
P.A. McSweeney R. Storb Mixed chimerism: Preclinical studies and clinical applications Biol. Blood Marrow Transplant 5 1999 192-203
I. Leykin B. Nikolic M. Sykes Mixed bone marrow chimerism as a treatment for autoimmune diabetes Transplant. Proc. 33 2001 120
C.S. Kuhr et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras Transplantation 73 2002 1487-1493
M. Andreani et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation Bone Marrow Transplant 25 2000 401-404
J.M. Zaucha et al. Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation Biol. Blood Marrow Transplant 7 2001 14-24
R. Huss et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia Bone Marrow Transplant 18 1996 767-776
F. Baron M.-T. Little R. Storb Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning Blood Rev. 19 2005 153-164
G.E. Georges et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation Blood 95 2000 3262-3269
M.-S. Tsoi R. Storb S. Dobbs E.D. Thomas Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplantation Nature 292 1981 355-357
B.D. Johnson M.C. Konkol R.L. Truitt CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT Biol. Blood Marrow Transplant 8 2002 525-535
A. Takatu et al. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia Biol. Blood Marrow Transplant 9 2003 674-682
F. Weissinger B.M. Sandmaier D.G. Maloney W.I. Bensinger T. Gooley R. Storb Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings Blood 98 2001 3584-3588
F. Baron et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood 104 2004 2254-2262
F. Baron B.M. Sandmaier Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning Curr. Opin. Hematol. 12 2005 435-443
M.B. Maris et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2003 2021-2030
F. Baron et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia Biol. Blood Marrow Transplant 11 2005 272-279
F. Baron et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation Leukemia 19 2005 822-828
M.B. Maris et al. Unrelated donor peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates Blood 104 Pt 1 2004 503a [Abstract 1818]
R.S. Hill et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease Blood 67 1986 811-816
F. Baron et al. Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning Biol. Blood Marrow Transplant 11 2005 11 (Suppl., Abstract 31)
W.A. Bethge et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Blood 103 2004 790-795
B.M. Sandmaier et al. Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyte infusion (DLI) Blood 104 Pt 1 2004 57a [Abstract 186]
M.P. Devetten J.M. Vose Graft-versus-host disease: How to translate new insights into new therapeutic strategies Biol. Blood Marrow Transplant 10 2004 815-825
M.R. Pelot et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Biol. Blood Marrow Transplant 5 1999 133-143
M. Mielcarek et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756-762
R.H. Collins Jr. et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J. Clin. Oncol. 15 1997 433-444
M.M. Horowitz et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555-562
W.J. Hogan et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients Blood 103 2004 78-84
C.R. Parikh et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation Am. J. Kidney Dis. 45 2005 502-509
T. Fukuda et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation Blood 102 2003 2777-2785
J.W. Chien M.B. Maris B.M. Sandmaier D.G. Maloney R.F. Storb J.G. Clark Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation Biol. Blood Marrow Transplant 11 2005 288-296
M.L. Sorror et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplant comorbidities Blood 104 2004 961-968
R. Diaconescu et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors Blood 104 2004 1550-1558
M.L. Sorror et al. Hematopoietic cell transplantation-specific comorbidity index: A new tool for risk assessment before allogeneic HCT Blood 106 2005 2912-2919
M.L. Sorror et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT Biol. Blood Marrow Transplant 11 Suppl. 1 2005 23-24
C. Junghanss et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood 99 2002 1978-1985
C. Junghanss et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study Biol. Blood Marrow Transplant 8 2002 512-520
F. Baron R. Storb Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced intensity conditioning Clin. Adv. Hematol. Oncol. 3 2005 799-813
D.W. Niederwieser et al. Treatment for acute myelogenous leukemia by low dose irradiation based conditioning and hematopoietic cell transplantation from related and unrelated donors Blood 104 Part 1 2004 840a (Abstract 3074)
B.L. Scott et al. Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multilineage dysplasia following MDS (tAML) Blood 104 Pt 1 2004 638a [Abstract 2320]
F.R. Kerbauy et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML Leukemia 19 2005 990-997
M.L. Sorror et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia J. Clin. Oncol. 23 2005 3819-3829
M.B. Maris et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood 104 2004 3535-3542
A.M. Carella et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma J. Clin. Oncol. 18 2000 3918-3924
D.G. Maloney et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood 102 2003 3447-3454
G.E. Georges et al. Nonmyeloablative unrelated donor hematopoietic cell transplantation (HCT) for patients (pts) with poor risk, relapsed or refractory multiple myeloma Blood 104 Pt 1 2004 754a [Abstract 2756]
U. Hegenbart et al. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria Biol. Blood Marrow Transplant 9 2003 689-697
C. Vermylen G. Cornu A. Ferster J. Ninane E. Sariban Bone marrow transplantation in sickle cell disease: The Belgian experience Bne Marrow Transplant 12 Suppl. 1 1993 116-117
R. Iannone et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia Biol. Blood Marrow Transplant 9 2003 519-528
J.T. Horan J.L. Liesveld P. Fenton N. Blumberg M.C. Walters Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin Bone Marrow Transplant 35 2005 171-177
M. Cavazzana-Calvo et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease Science 288 2000 669-672
A. Aiuti et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning Science 296 2002 2410-2413
C. Antoine et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99 Lancet 361 2003 553-560
P.A. Horn J.C. Morris T. Neff H.-P. Kiem Stem cell gene transfer-efficacy and safety in large animals studies Mol. Ther. 10 2004 417-431
H.-P. Kiem et al. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: No progression to clonal hematopoiesis or leukemia Mol. Ther. 9 2004 389-395
A.E. Woolfrey M. Pulsipher H.D. Ochs R. Storb Intensive post-grafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts in patients with primary immunodeficiency Clin. Invest. Med. 27 2004 [Abstract 4557]
A.E. Woolfrey R.A. Nash J.E. Sanders H.D. Ochs B. Thomson R. Storb A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders Blood 98 Pt 1 2000 784a [Abstract 3390]
J.N. Barker D.J. Weisdorf T.E. Defor B.R. Blazar J.S. Miller J.E. Wagner Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning Blood 102 2003 1915-1919
J.E. Wagner J. Barker Umbilical cord blood transplantation after a non-myeloablative therapy in high risk adults Biol. Blood Marrow Transplant 10 2004 733-734
P.V. O'Donnell et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide Biol. Blood Marrow Transplant 8 2002 377-386
C. Carvallo et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors Blood 103 2004 1560-1563
D.R. Couriel et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Biol. Blood Marrow Transplant 10 2004 178-185
J.A. Perez-Simon et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation Blood 102 2003 1108-1113
M. Mohty et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen Blood 102 2003 470-476
J.A. Perez-Simon et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders Blood 100 2002 3121-3127
C. Crawley et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT Blood 105 2005 4532-4539
M. Mohty et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: A donor vs no donor comparison Leukemia 19 2005 916-920
A.Y.L. Ho et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning Blood 104 2004 1616-1623
D.A. Jacobsohn R. Duerst W. Tse M. Kletzel Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children Lancet 364 2004 156-162
M.E. Horwitz et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft N. Engl. J. Med. 344 2001 881-888
K. Rao et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen Blood 105 2005 879-885
P. Veys K. Rao P. Amrolia Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning Bone Marrow Transplant 35 Suppl. 1 2005 S45-S47
S. Shenoy et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders Bone Marrow Transplant 35 2005 345-352
M. Bleakley S.R. Riddell Molecules and mechanisms of the graft-versus-leukaemia effect Nat. Rev. Cancer 4 2004 371-380
C. Rossig M.K. Brenner Genetic modification of T lymphocytes for adoptive immunotherapy Mol. Ther. 10 2004 5-18
T. Neff et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model J. Clin. Invest. 112 2003 1581-1588
R.D. Huhn J.F. Tisdale B. Agricola M.E. Metzger R.E. Donahue C.E. Dunbar Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning Hum. Gene Ther. 10 1999 1783-1790
B.M. Sandmaier R. Storb Nonmyeloablative therapy and hematopoietic cell transplantation for hematologic disorders K.G. Blume S.J. Forman F.R. Appelbaum Thomas' Hematopoietic Cell Transplantation 2004 Blackwell Sci. Oxford 1164-1176